Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Free Cash Flow: 2021-2025

Historic Free Cash Flow for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $38.0 million.

  • Krystal Biotech's Free Cash Flow fell 35.81% to $38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.2 million, marking a year-over-year increase of 205.73%. This contributed to the annual value of $114.9 million for FY2024, which is 214.23% up from last year.
  • Latest data reveals that Krystal Biotech reported Free Cash Flow of $38.0 million as of Q3 2025, which was down 25.32% from $50.8 million recorded in Q2 2025.
  • Krystal Biotech's Free Cash Flow's 5-year high stood at $59.1 million during Q3 2024, with a 5-year trough of -$61.8 million in Q4 2021.
  • Over the past 3 years, Krystal Biotech's median Free Cash Flow value was $7.4 million (recorded in 2024), while the average stood at $11.6 million.
  • As far as peak fluctuations go, Krystal Biotech's Free Cash Flow tumbled by 237.40% in 2022, and later soared by 1,287.50% in 2025.
  • Krystal Biotech's Free Cash Flow (Quarterly) stood at -$61.8 million in 2021, then surged by 55.41% to -$27.5 million in 2022, then surged by 71.22% to -$7.9 million in 2023, then soared by 763.95% to $52.6 million in 2024, then slumped by 35.81% to $38.0 million in 2025.
  • Its last three reported values are $38.0 million in Q3 2025, $50.8 million for Q2 2025, and $24.8 million during Q1 2025.